Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dynamic ctDNA-guided Targeted Therapy in DLBCL
NCT06748521Phase 2Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of orelabrutinib, decitabine, lenalidomide and tucidinostat in diffuse large B-cell lymphoma (DLBCL), sponsored by Ruijin Hospital. Primary endpoint: Complete Response Rate. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
orelabrutinibdecitabinelenalidomidetucidinostat
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06748521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06748521.